Repatha Cost in Michigan 2026: What You'll Actually Pay

What Is the 2026 List Price of Repatha in Michigan?

Amgen's wholesale acquisition cost for evolocumab (Repatha) sits at approximately $580 per month in 2026, a figure that applies consistently across Michigan retail and specialty pharmacies. Almost no one pays that amount. Insurance negotiations, manufacturer assistance programs, and state Medicaid contracts routinely reduce the real out-of-pocket cost to single digits or zero.

Repatha is a PCSK9 inhibitor delivered as a subcutaneous injection. The two approved regimens are 140 mg every two weeks or 420 mg once monthly, both self-administered with a prefilled autoinjector or SureClick device. The drug is FDA-approved for adults with heterozygous or homozygous familial hypercholesterolemia (HeFH, HoFH) and for adults with established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering beyond maximally tolerated statin therapy. The Repatha prescribing information and approval history are available on the FDA accessdata portal.

The 2017 FOURIER trial (N=27,564) demonstrated that adding evolocumab to statin therapy reduced LDL-C by 59% and cut the composite risk of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization by 15% relative to placebo over a median 2.2 years [P<0.001]. FOURIER full results are published in the New England Journal of Medicine. That cardiovascular outcomes data is the clinical foundation on which every payer's coverage decision rests.

Specialty pharmacies dispensing Repatha in Michigan include CVS Specialty, Walgreens Specialty, and Accredo, among others. Because Repatha is classified as a specialty drug, most plans route it through a specialty pharmacy channel rather than a standard retail counter.

How Michigan Medicaid Covers Repatha

Michigan Medicaid covers evolocumab, but requires prior authorization. The coverage applies to two populations: patients with a confirmed diagnosis of familial hypercholesterolemia and patients with established ASCVD who have not reached LDL-C goals on maximally tolerated statin therapy, with or without ezetimibe.

Prior authorization criteria under Michigan Medicaid's Pharmaceutical Services program generally require documentation of a qualifying diagnosis, evidence that statin therapy was tried and either failed to achieve target LDL-C or was not tolerated due to adverse effects, and a prescriber attestation. Approvals are typically granted for 12 months and require re-authorization. Michigan Medicaid pharmacy benefit details are maintained by the Michigan Department of Health and Human Services.

The American College of Cardiology and American Heart Association 2019 guideline on the primary prevention of cardiovascular disease states: "For patients with LDL-C levels persistently 70 mg/dL or higher despite maximally tolerated statin and ezetimibe therapy, it is reasonable to add a PCSK9 inhibitor." That guideline is available via the American Heart Association journals. Michigan Medicaid's PA criteria broadly align with those thresholds.

Patients enrolled in Michigan's Healthy Michigan Plan (Medicaid expansion) are covered under the same pharmaceutical services umbrella. Dual-eligible patients covered by both Medicare and Medicaid may access Repatha through Medicare Part D with cost-sharing assistance from the Low Income Subsidy (Extra Help) program, which can reduce monthly Part D out-of-pocket costs to a few dollars. Medicare Part D Low Income Subsidy information is available at the Social Security Administration site and confirmed by CMS. CMS data on PCSK9 inhibitor Medicare coverage shows steadily expanding access since the 2016 approval cycle.

Approval timelines vary. Under Michigan Medicaid managed care, the three major managed care organizations handling pharmacy (Molina Healthcare of Michigan, Blue Cross Complete of Michigan, and Meridian Health Plan) each have their own PA portals, but all must comply with state formulary requirements. PA decisions are required within 72 hours for urgent requests and 14 days for standard requests under federal Medicaid managed care rules. Federal PA timelines are codified in 42 CFR 438.210.

Which Private Insurance Plans Cover Repatha in Michigan?

Most commercial plans available through Michigan's health insurance exchange and employer-sponsored plans cover evolocumab on Tier 4 or Tier 5 (specialty tier), which typically means a percentage-based coinsurance rather than a flat copay. Without the Amgen savings card, a patient paying 25% coinsurance on a $580 list price would owe $145 per month, but that rarely reflects the actual negotiated price, which insurers negotiate well below list.

Blue Cross Blue Shield of Michigan covers evolocumab with PA on its commercial formularies. Priority Health, HAP (Health Alliance Plan), and McLaren Health Plan similarly require PA and place Repatha on a specialty tier. Formulary placement and PA criteria change annually with each plan's October formulary update for the following plan year, so verifying coverage for the 2026 plan year directly with your insurer or through Michigan's SERFF database is worth doing before filling the first prescription.

The ACC/AHA Cholesterol Guideline notes: "PCSK9 inhibitors are effective and generally well-tolerated; however, their high cost has been a barrier to access." That statement appears in the 2018 AHA/ACC Cholesterol Clinical Practice Guideline. That cost barrier is precisely why the manufacturer savings program and state Medicaid coverage exist as parallel access pathways.

Patients denied coverage can appeal. Under Michigan insurance law and the Affordable Care Act, insurers must offer an internal appeal and an independent external review. The Michigan Department of Insurance and Financial Services handles external review requests. Michigan DIFS complaint and external review information is available at michigan.gov/difs.

How the Amgen Savings Card Works for Michigan Patients

Amgen's Repatha savings card is the single most effective cost-reduction tool for commercially insured Michigan patients. Eligible patients pay $0 per month for their Repatha prescription if their commercial insurance covers any portion of the cost. Patients whose insurance does not cover Repatha may pay $550 per month under the card, which does not help much given the $580 list price. The program is designed to eliminate, not reduce, the insured patient's cost share.

Eligibility requirements are specific. The card is available only to patients with commercial (private) insurance. Medicare, Medicaid, Tricare, and other government-funded insurance programs are excluded by federal anti-kickback statute rules. Income is not a factor. The patient must be a U.S. resident and must be prescribed Repatha by a licensed prescriber. Amgen's patient support program terms are described on the Amgen Assist 360 portal.

For uninsured or underinsured Michigan patients, Amgen's Repatha Patient Assistance Program provides free drug to qualifying patients based on income. Applications are submitted through the Amgen Assist 360 program. NeedyMeds and the manufacturer's own portal both list current eligibility thresholds, which are updated annually.

A 2022 analysis in JAMA Cardiology found that PCSK9 inhibitor utilization increased substantially after manufacturer copay assistance programs were introduced, suggesting cost was the primary access barrier rather than clinical ineligibility. That analysis is indexed on PubMed. Michigan prescribers report similar patterns: patients who would otherwise decline a prescription accept it once they learn the $0 copay option exists.

Is Compounded Evolocumab Legal in Michigan?

Compounded evolocumab from a Michigan-licensed 503A pharmacy is legal under current federal and state rules, provided the compounding pharmacy holds an active Michigan Board of Pharmacy license and compounds the drug in accordance with USP <797> sterile compounding standards.

Section 503A of the federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound drugs for individual patients based on a valid prescription, even when an FDA-approved commercial version exists. The FDA's 503A compounding guidance is available at fda.gov. Evolocumab is not on the FDA's list of drugs that may not be compounded under 503A as of January 2025, meaning compounding is permissible.

The Michigan Board of Pharmacy licenses sterile compounding pharmacies under state law consistent with federal standards. Michigan Board of Pharmacy licensing requirements are listed at michigan.gov/lara. A prescription from a Michigan-licensed prescriber to a licensed 503A pharmacy for compounded evolocumab is legally valid in Michigan.

Cost is the main reason patients and clinicians explore compounded versions. Some 503A compounding pharmacies offer compounded evolocumab at substantially lower prices than the branded product, and in some clinical programs the cost to the patient may be zero through bundled pricing arrangements. Potency, sterility, and bioavailability data for compounded evolocumab preparations are not available from FDA-reviewed clinical trials, which is a meaningful difference from the branded product's 27,564-patient FOURIER outcomes database. FOURIER trial results, NEJM 2017.

Patients choosing compounded evolocumab should confirm the pharmacy's Michigan license, request a certificate of analysis for each batch, and discuss the absence of Phase III outcomes data for the compounded formulation with their prescriber.

Can a Michigan Patient Get Repatha via Telehealth?

Yes. Michigan law permits telehealth prescribing of Repatha. A Michigan-licensed prescriber conducting a synchronous audio-video visit may issue a prescription for evolocumab if a valid prescriber-patient relationship exists and the clinical evaluation supports the prescription.

Michigan's telehealth statute (MCL 333.16285) allows prescribing via telehealth without a prior in-person visit for most drug categories, including specialty injectables. Michigan's telehealth statutory framework is summarized by the Michigan Legislature online. Repatha is not a controlled substance, so the federal Ryan Haight Act requirements for in-person evaluation before prescribing do not apply.

Telehealth cardiology services and direct-to-patient platforms operating in Michigan can conduct lipid panel reviews, assess ASCVD risk using the ACC/AHA Pooled Cohort Equations, and prescribe Repatha within the same visit. The prescriber would still need documented evidence of an LDL-C value, a qualifying diagnosis or ASCVD event history, and a record of prior statin therapy. ACC/AHA risk calculator methodology is described in the 2013 Pooled Cohort Equations paper in Circulation.

A telehealth prescription routes to a specialty pharmacy by e-prescription, same as an in-person prescription. Turnaround from prescription to delivery is typically 3 to 5 business days with most specialty pharmacies serving Michigan patients.

What Is the Cheapest Way to Get Repatha in Michigan?

The answer depends on insurance status. Here is how the pathways rank by likely monthly out-of-pocket cost in Michigan in 2026.

Commercially insured patients with Amgen savings card eligibility pay $0 per month. That is the lowest possible cost for the branded product. Amgen Assist 360 eligibility information.

Michigan Medicaid patients who obtain prior authorization typically pay $0 to $3 per month in copays under standard Medicaid cost-sharing rules. Michigan Medicaid beneficiary cost sharing is governed by 42 CFR 447.50-82.

Medicare Part D patients without Low Income Subsidy face a more variable cost. In 2026, after the Inflation Reduction Act redesign caps out-of-pocket drug spending at $2,000 annually for Part D enrollees, the effective monthly cost for Repatha may range from roughly $60 to $167 depending on plan tier placement and where in the benefit year the patient is. IRA Part D redesign details are at CMS.

Uninsured patients who qualify for Amgen's patient assistance program receive the drug free. Those who do not qualify face the $580 list price, making compounded evolocumab from a 503A pharmacy the most cost-accessible alternative. NeedyMeds.org lists Amgen's assistance program.

GoodRx and similar discount card services do not meaningfully reduce Repatha's price because it is a specialty biologic. GoodRx prices for evolocumab in Michigan are typically within a few dollars of list.

The following decision framework summarizes the cost pathway based on insurance status for Michigan patients in 2026:

Commercially insured: Apply for Amgen savings card before first fill. Expected cost: $0/month. Michigan Medicaid: Submit PA documentation with LDL-C, diagnosis, and statin trial record. Expected cost: $0 to $3/month after approval. Medicare Part D: Enroll in a plan with Repatha on formulary. Apply for Extra Help if income-eligible. Expected cost: $0 to $167/month depending on subsidy status and plan year timing. Uninsured, income-eligible: Apply to Amgen Patient Assistance Program. Expected cost: $0. Uninsured, income-ineligible: Discuss compounded evolocumab from a Michigan-licensed 503A pharmacy. Confirm batch sterility certificates. Expected cost: varies by pharmacy.

LDL Targets and Why They Matter for Coverage Approval

Understanding LDL-C thresholds helps Michigan patients and prescribers build a successful PA submission. Both commercial and Medicaid payers in Michigan align their criteria with the 2018 AHA/ACC Cholesterol Guideline thresholds.

For patients with established ASCVD considered very high risk, the guideline recommends an LDL-C goal of less than 70 mg/dL. If LDL-C remains at 70 mg/dL or higher on maximally tolerated statin plus ezetimibe, adding a PCSK9 inhibitor is a Class IIa recommendation. 2018 AHA/ACC Cholesterol Guideline, Circulation.

For HeFH patients, the threshold for adding a PCSK9 inhibitor after statin plus ezetimibe is also LDL-C at or above 100 mg/dL in the presence of ASCVD, or 130 mg/dL in the absence of ASCVD. A 2020 meta-analysis in the European Heart Journal (N=176,000 patient-years of PCSK9 inhibitor exposure across FOURIER and ODYSSEY OUTCOMES) confirmed a 19% relative risk reduction in major adverse cardiovascular events per 1 mmol/L LDL-C reduction. That meta-analysis is indexed on PubMed.

Michigan Medicaid PA forms ask specifically for the baseline LDL-C on maximally tolerated statin therapy and the LDL-C on statin plus ezetimibe if the patient trialed both. Attaching two dated lab reports with LDL-C values and a note documenting statin dose and duration significantly reduces PA denial rates.

A 2021 analysis published in JAMA Network Open found that 54% of initial PCSK9 inhibitor PA requests were denied, but 78% of those denials were overturned on appeal when clinical documentation was complete. That study is available on PubMed. Submitting a complete PA the first time, with all required lab values and documented statin trial, is the most reliable way to avoid a denial cycle.

Side Effects and Monitoring Relevant to Michigan Prescribers

Evolocumab is generally well tolerated. The most common adverse effects in FOURIER were injection-site reactions (2.1% evolocumab vs. 1.6% placebo) and nasopharyngitis (11.2% vs. 11.3%), the latter essentially identical between groups. FOURIER safety data, NEJM 2017. Neurocognitive adverse events were examined in the EBBINGHAUS sub-study (N=1,974) and found to be no different from placebo on the Cambridge Neuropsychological Test Automated Battery. EBBINGHAUS results are on PubMed.

Monitoring after initiation consists of a fasting lipid panel 4 to 12 weeks after starting therapy to confirm LDL-C response, then every 3 to 12 months thereafter. No hepatic or renal monitoring beyond standard care is required. These monitoring intervals are described in the ACC/AHA guideline.

Patients on anticoagulants, immunosuppressants, or other biologics do not face pharmacokinetic interactions with evolocumab because it is a monoclonal antibody cleared by the reticuloendothelial system rather than CYP450 enzymes. FDA prescribing information for Repatha.